Gianmarco Abbadessa, MD, University of Campania Luigi Vanvitelli, Naples, Italy, discusses the ongoing search for potential biomarkers to tailor and monitor treatment for multiple sclerosis (MS). Currently, such treatments follow a fixed schedule and dosage, lacking biomarkers to guide therapeutic decisions. Dr Abbadessa mentions prior findings linking body mass index (BMI) and B-cell kinetics, as well as associations between baseline immune subsets and subsequent B-cell behavior. The crux of the study presented is an exploration of polymorphisms in the gene encoding the FC receptor of immunoglobulins (FCGR3A-V158F) and their potential impact on B-cell kinetics and ocrelizumab activity. Preliminary findings suggest that these gene variations might influence B-cell repopulation, though they might not correlate directly with disease activity. Such insights can be instrumental when considering future treatment modifications based on B-cell kinetics. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть